Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a...
Transcript of Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a...
![Page 1: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/1.jpg)
Radiopharmaceutical Dosimetry
by
Barry W. Wessels, Ph.D.Professor of Radiation Oncology
Case Western Reserve University
![Page 2: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/2.jpg)
MIRDMedical Internal Radiation Dose
• Recognized as a method to perform dose calculation for internal emitters
• Name of a standing committee of the Society of Nuclear Medicine
![Page 3: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/3.jpg)
Calculation of Absorbed Dose to an Organ
Organ of Mass
RadiationIonizing from
AbsorbedEnergy
DoseAbsorbed =
![Page 4: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/4.jpg)
Source and Target Organs
For the administration of a radiopharmaceuticalto a human, the time-dependent localization of activity in an organ is designated a source organ.
The organ that is the recipient of this radiate energy from the source organs is called a targetorgan.
![Page 5: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/5.jpg)
Self Dose
Any one organ can be simultaneously designated as both a source and target organ. In this case, the energy deposited in that organ is called the self dose.
![Page 6: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/6.jpg)
Sources and Targets ( Self –Irradiation)
![Page 7: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/7.jpg)
Source and Targets – Cross Irradiation
![Page 8: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/8.jpg)
Sources and Targets (Combination)
![Page 9: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/9.jpg)
Absorbed Fraction
The fraction of the energy emitted by source and deposited in the target is called the absorbedfraction ( ).iφ
![Page 10: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/10.jpg)
Absorbed Fraction – Example 1
![Page 11: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/11.jpg)
Absorbed Fraction – Example 2
![Page 12: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/12.jpg)
Absorbed Fraction – Example 3
![Page 13: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/13.jpg)
Absorbed Fraction(continued)
• Type and energy of the radiation• Size, shape and composition of the source
and target• Distance between source and target as well
as the type of material separating them
This depends on:
![Page 14: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/14.jpg)
Cumulated Activity (Ã)
The Cumulated Activity is represented by the area under the time activity curve and has the dimensions of activity x time (uCi • hr)
![Page 15: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/15.jpg)
Cumulated Activity (cont)
Area under the curve
Time
Activity
![Page 16: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/16.jpg)
Cumulated Activity (cont)
The cumulated activity ( ) in an organ h can be mathematically expressed as:
∫∞
=0
)(~ dttAA hh
hA~
![Page 17: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/17.jpg)
Cumulated Activity (cont)Measurement of radioactivity distribution and turnover within human tissues is a major task.
Models of Cumulated Activity:1. Uptake by organ is instantaneous with no
biologic excretion
2. Uptake by organ is instantaneous with elimination by biologic excretion only
3. Uptake by organ is instantaneous with removal by both physical decay and biologic excretion
4. Uptake by organ is not instantaneous
![Page 18: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/18.jpg)
Dose Equation
Hence, the radiation energy emitted by the source activity cumulated ( ) over the time interval of interest is given by:
hA~
tiondisintegranuclear per emittedenergy mean total theis ∆ where
A~ h∆
![Page 19: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/19.jpg)
Dose Equation (cont.)
If we now consider a radiopharmaceutical that emits several kinds of radiation (e.g. beta and gamma), each is characterized by its own mean energy per particle ( E i ) and number of particles (n i), then:
unitson dependent is and
constant a isK whereiii EnK=∆
![Page 20: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/20.jpg)
Dose Equation(continued)
Therefore, the energy absorbed by a target (rk) from a source region (rh) irradiation is given by:
iihA φ∆~
![Page 21: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/21.jpg)
Absorbed Dose to Organ (Single Source)
The mean absorbed dose ( ) to target organ k with mass (Mk ) from a single source organ h is given by:
k
iihk
MAD φ∆=~
kD
![Page 22: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/22.jpg)
Absorbed Dose to Organ(Single Source)
To sum the contributions for all radiations from source h to target k:
k
iiih
kM
A~
D∑ φ∆
=
![Page 23: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/23.jpg)
S FactorThe previous equation may be separated
into two parts 1) cumulated activity and 2) those factors dependent on radionuclide properties relative to a size and position of various organ in a model phantom. This latter quantity is labeled the S factor and is defined mathematically as:
ki
iihk M/)rr(S ∑ φ∆=←
![Page 24: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/24.jpg)
S Factor(continued)
If we also define a specific absorbed fraction as:
,
then the dose equation simplifies to be :
k
i
Mφ=Φ
![Page 25: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/25.jpg)
MIRD Dose Equation(Simplified)
Where: Ã is the Cumulated Activity
and
S is the mean absorbed dose per cumulated activity or S-factor
SAD ×= ~
![Page 26: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/26.jpg)
Dose Equation (cont)(Multiple Sources)
Ordinarily there will be many source organs (rh) contributing dose to the target rk. Hence the total dose equation summed over all sources is given by:
)(D)(__
hh
kk rrrD ∑ ←=
![Page 27: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/27.jpg)
Residence Time
Act
ivity
Ao
Timeττττh
Ah(t)
The concept of residence time (τh) has also found to be useful to describe an organ into which the activity A0 is administered at time t = 0. The area under Ah(t) equals the area of the rectangle.
![Page 28: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/28.jpg)
Residence Time
The residence time in source organ h is defined as:
where A0 is the administered activity and Ãh is the cumulated activity in organ h.
0
~
AAh
h =τ
![Page 29: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/29.jpg)
Residence Time (τ)
When uptake phase can be neglected and maximal source activity is ,hA
0
)(443.1A
AT heffhh =τ
![Page 30: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/30.jpg)
Residence Time (τ)(continued)
In case of bolus administration where all theactivity ( ) is located in organ at T = 0 (e.g. blood),
effhh T )(443.1=τ )( 0AAh =
τ is simply the effective mean lifetime (1.443 T) of the activity in the organ multiplied by . 0A
0A
![Page 31: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/31.jpg)
Practical Example
This example illustrates a method for estimating absorbed dose to an organ from the biologic behavior of a radiopharmaceutical.
Injected Tc - 99m sulfur colloid is deposited in the liver, which becomes the source organ. We will calculate the dose from the source organ to target organs, which include the self dose from the liver.
![Page 32: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/32.jpg)
Practical Example(cont)
SASAD τ0~ ==
The dose from the source organ, liver, to itself as the target organ (self-dose) and to other organs of the body can be calculated from the basic equation:
S
AD
τ0
mean dose
administered activity
residence time
S - Factor
![Page 33: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/33.jpg)
Example – cont.
Assume the injection of 1 mCi of Tc-99 m sulfur colloid and that 85 % remains in the liver.
![Page 34: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/34.jpg)
Calculation of Residence TimeResidence time is defined as:
where is the cumulated activity in organ h, which is defined as the sum of the activity at each moment in time:
.
0
~
AAh
h =τ
hA~
∫∞
+−=0
)(~ dteAA thh
bλλ
![Page 35: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/35.jpg)
Residence Time (cont)If is defined as the physical decay constant and
is defined the biologic clearance constant.
In this example, there is no biologic clearance from the liver, so
λ
bλ
0=bλ
![Page 36: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/36.jpg)
Calculation of Residence Time(continued)
Integration gives:
From the physical half-life T1/2p of 6.02 hours (h) for , we can calculate as:
∫∞
− ==0
~λ
λ hthh
AdteAA
Tcm99 λ1
2/1
115.002.6693.02ln −=== h
hT p
λ
![Page 37: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/37.jpg)
Calculation of Residence Time(continued)
We were given . Thus,
hhA
AAA hh 39.7
115.085.01~
100
==== −λτ
85.00 =AAh
![Page 38: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/38.jpg)
Target organ rad/µCi hGI (ULI wall) 2.5E-06
GI (LLI wall) 2.3E-07
Kidneys 3.9E-06
Liver 4.6E-05
Lungs 2.5E-06
S Values for Tc-99mSource Organ (Liver)
![Page 39: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/39.jpg)
Practical Example - MIRDThe absorbed dose can now be
calculated.
For the liver:
hCirad106.4Sh39.7
)mCi1(orCi000,1A
5liver
0
µ×=
=τµ=
−
)liverliver(SAD 0 ←τ=
![Page 40: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/40.jpg)
Solution - Liver Dose
radhCiradhCi
SAD liverliver
340.0)106.4)(39.7)(101( 53
0
=××=
=− µµ
τ
![Page 41: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/41.jpg)
Practical Example - MIRD
Similarly, for the kidney dose
hCirad109.3)LiverKidney(Sh39.7
)mCi1(orCi000,1A
6
0
µ×=←
=τµ=
−
)LiverKidney(SAD 0 ←τ=
![Page 42: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/42.jpg)
Solution - Kidney Dose
radhCiradhCi
SAD kidneykidney
029.0)109.3)(39.7)(101( 63
0
=××=
=− µµ
τ
![Page 43: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/43.jpg)
Summary - Dose Equation
1. Biological Parameters ( )• The time that activity spends in source organ
• Depend on physiologic behavior of radiopharmaceutical radioactive decay
2. Physical Parameters ( value)Depend on: • nature of the radiations
• their absorption characteristics
• the anatomic model
SAD ~=
S
A~
Dose equation consists of two parameters:
![Page 44: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/44.jpg)
Summary (2/3)
• Knowledge of activity distribution in body• Activity deposited in organ of interest can
be estimated by:– Extrapolation from animal data– External measurements using a scintillation
camera in planar or SPECT modes– Estimation through use of a compartmental
model– Measurement of excretory fluids
I. Biologic Distribution Data
![Page 45: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/45.jpg)
Summary (3/3)II. Physical Parameters
1. Nuclear parameters for particular radionuclide: type of particle, number and energy of particles per transition, and energy emitted per transition (MIRD: Radionuclide Data and Decay Schemes, The Society of Nuclear Medicine, 1989).
2. Source/target organ configuration: absorbed fraction (MIRD Pamphlets No. 3 [1968], 5 revised [1978], 8 [1971] and Cristy and Eckerman, ORNL Pub. [1987]).
3. S values (MIRD Pamphlet No. 11 [1975]).
![Page 46: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/46.jpg)
Reference List1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For
Absorbed Dose Calculations, Revised Edition, The Society of Nuclear Medicine, New York, New York (1991).
2. Siegel JA, Thomas SR, Stubbs JB et al. MIRD Pamphlet No.16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med, 40, 37s –61 s (1999).
3.. Bolch WE, Bouchet LG, Robertson JS et al. MIRD Pamphlet No. 17: The Dosimetry of Nonuniform Activity Distribution –Radionuclide S values at the Voxel Level. J Nucl. Med, 40 , 11s – 36s (1999)
![Page 47: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/47.jpg)
Methods for Computing Absorbed Dose from Non-Uniform Activity or
Gradient Activity Distributions
1. Dose Point Kernels for Electrons and Photons
2. Applications of Direct Monte Carlo Radiation Transport Codes
3. The Voxel S Value Approach
)voxelvoxel(SA~)voxel(D hk
N
0hvoxelk k
←•=∑=
![Page 48: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/48.jpg)
Point Kernel Approach (1)• Dose point kernel:
Radial distribution of absorbed dose around isotropic point source in an infinite homogeneous medium
![Page 49: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/49.jpg)
Point Kernel Approach (2) Calculation methods
Transport equationsOR
Monte Carlo transport codes
Lookup TablesOR
Empirical Solutions
![Page 50: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/50.jpg)
Point Kernel Approach (3)Nonuniform Activity Distribution
• Convolution of activity data with dose point kernel
Dose Point Dose Point KernelKernel
rh
rk
= *rh
rk
DoseDose ActivityActivity
![Page 51: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/51.jpg)
Point Kernel Approach (5)
• Advantage– Fast computer time required for dose
calculation• Disadvantages
– Does not handle heterogeneities– Biased to spherical geometry– Geometry factors + dose convolution:
complicated
![Page 52: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/52.jpg)
Monte Carlo Approach (1)• Simulation of a random process:
– Transport of Electrons and Photons• Two widely used Monte Carlo code in Medical Physics
– EGS4: Electron Gamma Shower Version 4• Simulation of the electron-photon shower
– MCNP Version 4B • Coupled transport of photons and neutrons +
electrons• Differences:
– Physics of electron transport– Input / output
![Page 53: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/53.jpg)
Monte Carlo Approach (3)
• Advantages– Handle heterogeneities => very accurate– No longer biased to spherical geometry
• Disadvantages– Large amount of CPU time required– Still a complicated approach
![Page 54: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/54.jpg)
MIRD Voxel S value Approach (1)
MIRD Methodology
Tof MassTin DepositedEnergy DT =
Source: S
Target:T
TofMassT)in AbsorbedEnergy of(Fraction S)in emittedEnergy (TotalDT =
![Page 55: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/55.jpg)
MIRD Voxel S value Approach (3)
MIRD Methodology
( )STS A~D ST ←=
Define: S value
( ) ( )TS
T
mST
A~DSTS ←φ∆==←
Finally:
imaging PETor SPECT, planar, from derive A~ S
S value tabulated for Source/Target/Radionuclide
![Page 56: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/56.jpg)
MIRD Voxel S value Approach (4)
Nonuniform Activity Distribution
S valueS value
rh
rk
= *rh
rk
rh
rk
DoseDose ActivityActivity
( )∑ ←=sources all
sourcetarget sourcetargetSA~D
![Page 57: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/57.jpg)
MIRD Voxel S value Approach (5)
Nonuniform Activity Distribution• Advantages
– Use the simple MIRD dose calculation methodology
– Fast to perform (can use DFFT)– Accurate (S values match the geometry of
activity data)
• Disadvantages– Does not handle heterogeneities
![Page 58: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/58.jpg)
Application of Non-Uniform Dose Calculation Methods to Special Problems
1. Quantitative Autoradiograghy2. Local deposition of dose from alpha
and beta radiations3. Intravascular Brachytherapy – balloon
catheters4. Sub-organ dosimetry – Kidney, Lung,
Liver, GI, Brain and Bone Marrow
![Page 59: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/59.jpg)
MIRDOSE Update – M. Stabin• New version of MIRDOSE to be released this summer
(2001).• New name – OLINDA – Organ Level Internal Dose
Assessment (written in Java).• Linked to new RADAR (RAdiation Dose Assessment
Resource) on-line system for internal/ external dose assessment.
• Most MIRDOSE 3 models carried over.• New models included: MIRD head/brain, Yale voxel
phantom, prostate gland, peritoneal cavity, others.• Will be ONLY research/ teaching tool – separate,
smaller codes for clinical application will be developed and submitted for FDA approval.
![Page 60: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/60.jpg)
RADAR Web Sitewww.doseinfo-radar.com
• Decay data for >800 radionuclides• Absorbed fractions for 11 phantoms• Kinetic data for many radiopharmaceuticals• Dose factors (like MIRD S values) for all 800
nuclides and 11 phantoms• Fetal dose factors, skin dose factors, external
dose factors• Risk information, consent form language• On-line training courses – internal, external
dose• MORE! -------- M. Stabin – July 2001
![Page 61: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/61.jpg)
Internal Sources:
Kinetic Models -Radiopharmaceuticals
Kinetic Models -Occupational Radionuclides
Radionuclide Decay Data
Specific AbsorbedFractions - Phantoms
Dose ConversionFactors
External Source Configuration
Radiation Dose Estimates and Distributions
Linking of RadiationDoses to Biological Effects
External Sources:
Overview of the RADAR System - M. Stabin
![Page 62: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/62.jpg)
AnnouncementSeventh International Radiopharmaceutical
Dosimetry Symposium
http://www.doseinfo-radar.com/symphome.html
• April 17-19, 2002 in Nashville, TN• Topics include:
– Therapy with internal emitters– Dose effects, models– Cellular, small scale dosimetry– Kinetic, animal models– Regulatory issues
• Call for abstracts on web site – now until Sept 30, 2001.
![Page 63: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/63.jpg)
Fundamental Objectives forRadionuclide Therapy
Fundamental Objectives forRadionuclide Therapy
1. 1. To achieve appropriate treatment of disease through To achieve appropriate treatment of disease through delivery of radiation dose to a tolerable cytotoxic level:delivery of radiation dose to a tolerable cytotoxic level:
2. 2. To avoid or minimize toxic effects:To avoid or minimize toxic effects:Both as acute reactions and late effects.Both as acute reactions and late effects.
Defined endpointsDefined endpoints –– “Cure” or NED, increase in “Cure” or NED, increase in survival, control (full or partial), improvement in QOL survival, control (full or partial), improvement in QOL ( e.g. palliation).( e.g. palliation).
Knox S, Seminars in Radiation Oncology, 10 : pp 71 Knox S, Seminars in Radiation Oncology, 10 : pp 71 -- 167 (April 2000)167 (April 2000)
![Page 64: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/64.jpg)
Response Evaluation
•%%%% response, %%%% CR, PR, MR,Mixed, Stable
•Duration, time to need formore therapy, QOLimprovement
•Non-measurable disease-Time to progression
![Page 65: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/65.jpg)
QOL Forms: Functional Index
• 1. Has nausea affected your daily functioning?
• 2. How much is pain interfering with your daily activities?
• 3. Do you feel well enough to make a meal or do minor household repairs?
![Page 66: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/66.jpg)
Early Use of Radionuclides in TherapyEarly Use of Radionuclides in TherapyRadionuclideRadionuclide Disease TypeDisease Type Original/Early UseOriginal/Early Use
PP--3232 PolycythemiaPolycythemia Vera Vera 19361936
PP--3232 LymphoproliferativeLymphoproliferative 19381938
PP--3232 Bone PainBone Pain 19371937
SrSr--8989 Metastatic Cancer to BoneMetastatic Cancer to Bone 19411941
II--131131 HyperthyroidismHyperthyroidism 19421942
II--131131 Differentiated Thyroid CancerDifferentiated Thyroid Cancer 19441944(Remnant Ablation; Tumor/Metastases)(Remnant Ablation; Tumor/Metastases)
![Page 67: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/67.jpg)
1. High, fixed administered activity: 751. High, fixed administered activity: 75--150 150 mCimCi..
2. Low, fixed administered activity: ~30 2. Low, fixed administered activity: ~30 mCimCi
3. 3. AAoo calculated to provide a predetermined radiation calculated to provide a predetermined radiation dose. Requires knowledge of remnant mass, effective dose. Requires knowledge of remnant mass, effective halfhalf--time and 24time and 24--hr uptake.hr uptake.
4. Quantitative diagnostic work4. Quantitative diagnostic work--up: up: 131131I tracer to establish I tracer to establish patient specific parameters.patient specific parameters.
I-131 Treatment of Thyroid Cancer or Ablation of Thyroid Remnants
I-131 Treatment of Thyroid Cancer or Ablation of Thyroid Remnants
![Page 68: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/68.jpg)
Results in treating Thyroid Remnants
Results in treating Thyroid Remnants
•• Desired radiation dose:Desired radiation dose:
H.R.H.R.MaxonMaxon: 30,000 : 30,000 cGycGy ( ~81% control rate)( ~81% control rate)Others: 25,000 to 100,000 Others: 25,000 to 100,000 cGycGy
•• Complications:Complications:
-- Short term: Bone marrow depression; Acute or chronic Short term: Bone marrow depression; Acute or chronic sialdentissialdentis; thyroid storm (rare).; thyroid storm (rare).
-- Long Term: leukemia; Long Term: leukemia; azoospermiaazoospermia; pulmonary fibrosis.; pulmonary fibrosis.
![Page 69: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/69.jpg)
Phase I Study DesignPhase I Study DesignObjective : Determine Maximum Objective : Determine Maximum
Tolerated Dose (MTD)Tolerated Dose (MTD)Design : Design :
1. First dose level usually shows little 1. First dose level usually shows little or no toxicityor no toxicity
2. Fixed dose escalation in increments 2. Fixed dose escalation in increments of usually 20of usually 20--25%. 25%.
3. Dose based on patient specific parameters 3. Dose based on patient specific parameters e.g. e.g. mCimCi/kg; AUC for/kg; AUC for pharmacokinetics pharmacokinetics
curve or based on radiation dose to curve or based on radiation dose to normal organs.normal organs.
![Page 70: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/70.jpg)
Phase I Escalation ExamplesPhase I Escalation Examples
1. Y2B8 0.21. Y2B8 0.2-- 0.40.4 mCimCi/kg/kg�� 0.4mCi/kg = MTD0.4mCi/kg = MTD
2. I2. I--131131--antianti--B1 WB 25B1 WB 25--85cGy; calculated 85cGy; calculated from clearance rate, Phase II = 75cGyfrom clearance rate, Phase II = 75cGy
3. Seattle3. Seattle-- myeloablativemyeloablative therapy 15therapy 15--31Gy to 31Gy to
normal organs, 27Gy = 2nd critical organ normal organs, 27Gy = 2nd critical organ
MTDMTD
![Page 71: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/71.jpg)
Phase II Study DesignPhase II Study Design��Objective Objective -- define response rate define response rate
��MTD, next lower dose, or MTD, next lower dose, or modestly reduced to 80%modestly reduced to 80%
��1st 14 patients 1st 14 patients -- if no response if no response -- small small chance > 20% response rate. chance > 20% response rate. Number of responses in 1st 14 pt. Number of responses in 1st 14 pt. allows determination of how many to allows determination of how many to study for response rate 20% study for response rate 20%
![Page 72: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/72.jpg)
Modern Radionuclide Therapy
Modern Radionuclide Therapy
AA.. Systemic Radionuclide Therapy:Systemic Radionuclide Therapy:
(1) Benign Disease(1) Benign Disease
131131I sodium iodine:I sodium iodine: Graves’ disease; singleGraves’ disease; singlefunctioning nodule; toxic functioning nodule; toxic multinodular multinodular goitergoiter
3232P sodium phosphate:P sodium phosphate: PV; PV; thrombocytothemiathrombocytothemia..9090Y colloid: Y colloid: Severe arthritisSevere arthritis165165Dy ferric hydroxideDy ferric hydroxide:: Severe arthritisSevere arthritis
((McDougallMcDougall, , Sem Rad Onc Sem Rad Onc 1010, 2000), 2000)
![Page 73: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/73.jpg)
Modern Radionuclide Therapy
Modern Radionuclide Therapy
A.A. Systemic Radionuclide Therapy:Systemic Radionuclide Therapy:
(2) Malignant Disease(2) Malignant Disease131131I sodium iodine: I sodium iodine: ablation Thyroid CA, remnantablation Thyroid CA, remnant131131I MIBG: I MIBG: Metastatic neuroblastomaMetastatic neuroblastoma111111In In octreotideoctreotide: : neuroblastomaneuroblastoma3232P chronic phosphate: P chronic phosphate: Intracavity therapyIntracavity therapy8989Sr strontium chloride:Sr strontium chloride: Painful skeletal Painful skeletal metsmets153153Sm EDTPA: Sm EDTPA: Painful skeletalPainful skeletal metsmets
![Page 74: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/74.jpg)
Modern Radionuclide Therapy
Modern Radionuclide Therapy
BB. Systemic Radionuclide Therapy:. Systemic Radionuclide Therapy:Radioimmunotherapy Radioimmunotherapy -- (1) Solid Tumors(1) Solid Tumors
131131II--antianti--EGFR: EGFR: Recurrent Recurrent gliomas gliomas --CNS siteCNS site125125II--425: 425: Glioblastoma multiforme Glioblastoma multiforme -- CNSCNS186186ReRe--NRNR--LULU--10: 10: Ovary; breast, colon, lungOvary; breast, colon, lung9090YY--antianti--ferritin: ferritin: HepatomaHepatoma
125125II--1717--1A: 1A: GastrointestinalGastrointestinal9090YY--ChT84.66 antiChT84.66 anti--CEA: CEA: ColonColon
(Knox/Meredith, (Knox/Meredith, Sem Rad OncSem Rad Onc 1010, 2000), 2000)
![Page 75: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/75.jpg)
Modern Radionuclide Therapy
Modern Radionuclide Therapy
BB. Systemic Radionuclide Therapy:. Systemic Radionuclide Therapy:Radioimmunotherapy Radioimmunotherapy -- (2) B Cell Lymphoma(2) B Cell Lymphoma
NonmyloablativeNonmyloablative::131131I: I: LymLym--1; LL2; Anti1; LL2; Anti--B1; MB1B1; MB19090Y:Y: B1; 2B8; C2B8B1; 2B8; C2B8
MyloablativeMyloablative::131131I: B1; MB1; LL2; 1F5; BC8I: B1; MB1; LL2; 1F5; BC89090Y:Y: B1B1213213Bi: Bi: HuMHuM--195195
![Page 76: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/76.jpg)
Normal organ tolerance to radiation (cGy)
![Page 77: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/77.jpg)
Normal Organ Toxicity
![Page 78: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/78.jpg)
![Page 79: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/79.jpg)
![Page 80: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/80.jpg)
![Page 81: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/81.jpg)
Summary (4/4)
III. Schema to Calculate Absorbed Dose Estimates
References
Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine (MIRD Pamphlet No. 1, Revised [1976]).
Loevinger R, Budinger TF and Watson EE, MIRD Primer for Absorbed Dose Calculations, The Society of Nuclear Medicine, New York, NY (1991)
![Page 82: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/82.jpg)
Establishing the Role for Dosimetry in Radionuclide Therapy Today
Establishing the Role for Dosimetry in Radionuclide Therapy Today
Fundamental Questions Fundamental Questions for Consideration:for Consideration:
How might patient specific factors How might patient specific factors be used most appropriatelybe used most appropriately
in the optimization ofin the optimization ofradionuclide therapy ?radionuclide therapy ?
![Page 83: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/83.jpg)
Establishing the Role for Dosimetry in Radionuclide Therapy Today
Establishing the Role for Dosimetry in Radionuclide Therapy Today
Fundamental Questions Fundamental Questions for Consideration:for Consideration:
For a specific disease, patientFor a specific disease, patientclassification, and radionuclideclassification, and radionuclide
therapy, should there be therapy, should there be a standard treatment protocol ?a standard treatment protocol ?
![Page 84: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/84.jpg)
Starting Point for Radionuclide Therapy Determining the Administered Activity
Starting Point for Radionuclide Therapy Determining the Administered Activity
1. Fixed administered activity (1. Fixed administered activity (AAoo): ): Single administrationSingle administration
2. Fixed 2. Fixed AAoo with multiple with multiple readministrationreadministration dependent dependent upon patient response according to defined upon patient response according to defined indicators.indicators.
3.3. AAoo determined by basic patient specific parameters determined by basic patient specific parameters (e.g., body surface area, weight, target tissue mass)(e.g., body surface area, weight, target tissue mass)
4.4. AAoo determineddetermined by more extensive patient specific by more extensive patient specific parameters including parameters including biokinetics biokinetics and the desired and the desired radiation dose to be delivered.radiation dose to be delivered.
![Page 85: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/85.jpg)
The Role of Patient Specific Dosimetry in the Development of New Agents
The Role of Patient Specific Dosimetry in the Development of New Agents
•• Phase I Studies:Phase I Studies: Essential to establish Essential to establish human pharmacokinetics and dosimetry for human pharmacokinetics and dosimetry for safety in preparation for clinical trials.safety in preparation for clinical trials.
•• Phase II Studies:Phase II Studies: To be advise in limited To be advise in limited patient clinical trials to address the efficacy patient clinical trials to address the efficacy aspects.aspects.
•• Phase III Studies:Phase III Studies: Must show utility Must show utility
![Page 86: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/86.jpg)
Categories of Patient Specific Dosimetry
Categories of Patient Specific Dosimetry
Level 1:Level 1:
Measurement of the relevantMeasurement of the relevant biokinetic biokinetic parameters prior to therapy for use parameters prior to therapy for use in conjunction with standard anatomic in conjunction with standard anatomic and mathematical models to calculate and mathematical models to calculate radiation dose for extrapolation from radiation dose for extrapolation from the tracer study to the therapeuticthe tracer study to the therapeuticadministration.administration.
![Page 87: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/87.jpg)
Categories of Patient Specific Dosimetry
Categories of Patient Specific Dosimetry
Level 2:Level 2:
Extension of the database acquiredExtension of the database acquiredthrough Level 1 by determination ofthrough Level 1 by determination ofadditional anatomic and/or tissueadditional anatomic and/or tissuedistribution specific to the patient. distribution specific to the patient. To be used for minor adjustments to To be used for minor adjustments to the standard anatomic models prior the standard anatomic models prior to calculation of radiation dose. to calculation of radiation dose.
![Page 88: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/88.jpg)
Categories of Patient Specific Dosimetry
Categories of Patient Specific Dosimetry
Level 3 (and beyond):Level 3 (and beyond):
Definitive representation of the patientDefinitive representation of the patientthrough 3through 3--D techniques employing fusionD techniques employing fusionof physiologic images with high resolutionof physiologic images with high resolutionanatomic images. Ultimately, 3anatomic images. Ultimately, 3--D D voxelvoxelrepresentation of the patient with pointrepresentation of the patient with pointkernel or MC techniques used to derivekernel or MC techniques used to deriveS values for use in the radiation dose S values for use in the radiation dose calculations.calculations.
![Page 89: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/89.jpg)
How accurate are tracer studies?
1. Meredith- AIR ‘93 131LYM-1 ratio predicted/received - 0.91-1.38 Dose ratio
2. Eary- Med Phys ‘94 Percent error - 0.7- 28.6 in lung dose
3. Clark City of Hope- Med Phys ‘99 Concordance levels - 0.6 - 0.99
4. Macey IFN breast Ca, Percent change residence time in blood & WB diagnostic to Rx dose = 7-25%
![Page 90: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/90.jpg)
Marrow DosimetryBrief History in Time
1970 1980 1990 2000
Percent Variation in Calculation of Dose
700 %
200 % 25%
MIRD 5 and 11
Blood ModelNCI CONTRACT
MIRDOSE PROGRAMS
AAPM TASK GROUP / MIRD TG
Sgouros Model
![Page 91: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/91.jpg)
Multi-institutional Comparison of Bone Marrow Dosimetry
Results – 06-11-01Reporting Center No. of Patients Ratio ( Institution/ Task Group Value)
Institution A 2 0.78Institution B 1 1.06Institution C 1 0.87Institution D 1 0.80Institution E 10 1.16Institution G 2 0.65 Institution F 2 0.86
(updated Cs and HCT)
Average Ratio = 0.88 ± 0.06 (S.E.)
![Page 92: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/92.jpg)
Arguments For and Against Patient Specific Dosimetry Protocols
in the General Clinical Setting
Arguments For and Against Patient Specific Dosimetry Protocols
in the General Clinical Setting
Advantages:Advantages:•• Provide a quantitative description of individual Provide a quantitative description of individual
patient pharmacokinetics.patient pharmacokinetics.•• Allow individual estimation of radiation dose to Allow individual estimation of radiation dose to
target and normal tissues. target and normal tissues. •• Provides the prospect for optimized delivery of Provides the prospect for optimized delivery of
the desired therapeutic radiation dose while the desired therapeutic radiation dose while minimizing toxicity.minimizing toxicity.
•• Allow predictions re hospitalization required.Allow predictions re hospitalization required.
![Page 93: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/93.jpg)
Arguments For and Against Patient Specific Dosimetry Protocols
in the General Clinical Setting
Arguments For and Against Patient Specific Dosimetry Protocols
in the General Clinical Setting
Disadvantages:Disadvantages:•• Complexity of quantitative procedures.Complexity of quantitative procedures.•• Time and cost.Time and cost.•• Inconvenience to the patient.Inconvenience to the patient.•• Inherent components of error.Inherent components of error.•• Difficulty in transporting between Difficulty in transporting between
institutions as a universal technique.institutions as a universal technique.
![Page 94: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/94.jpg)
Potential Utility of Patient Specific Dosimetry in the Evaluation of
Radionuclide Therapy
Potential Utility of Patient Specific Dosimetry in the Evaluation of
Radionuclide Therapy•• Treatment PlanningTreatment Planning:: To predict dose, minimize To predict dose, minimize
toxicity, increase safety for patients who may toxicity, increase safety for patients who may have widely differing pharmacokinetics and have widely differing pharmacokinetics and clinical status.clinical status.
•• FollowFollow--up Evaluationup Evaluation:: To obtain a better To obtain a better understanding of patient outcome and enable an understanding of patient outcome and enable an informed decision on future therapeutic action.informed decision on future therapeutic action.
•• DoseDose--Response RelationshipsResponse Relationships:: To elucidate the To elucidate the relationship between absorbed dose and relationship between absorbed dose and response.response.
![Page 95: Dosimetry Radiopharmaceutical - AAPM: The American ... · biologic behavior of a radiopharmaceutical. ... 1. Loevinger R, Budinger TF and Watson EE. MIRD Primer For Absorbed Dose](https://reader031.fdocuments.us/reader031/viewer/2022021820/5ae2d8cc7f8b9a7b218c5fe7/html5/thumbnails/95.jpg)
Which Route to Go ? The Challenge Ahead ….
Which Route to Go ? The Challenge Ahead ….
G.L.G.L.DeNardoDeNardo, et. al. , et. al. Crit Crit Rev Rev Onc Onc Hem 2001Hem 2001
1. As long as simpler empirical methods provide safe 1. As long as simpler empirical methods provide safe and effective treatment, they should be considered and effective treatment, they should be considered valid.valid.
2. For those who would like to claim that patient 2. For those who would like to claim that patient specific dosimetry methods are superior, it is specific dosimetry methods are superior, it is necessary to demonstrate that the frequency of necessary to demonstrate that the frequency of excess toxicities and/or target tissue underexcess toxicities and/or target tissue under--treatment are significantly lower when treating at treatment are significantly lower when treating at the MTD with each approach.the MTD with each approach.